ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Satellos Bioscience Inc

Satellos Bioscience Inc (MSCL)

0.84
-0.01
(-1.18%)
Closed 13 November 8:12AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.84
Bid
0.82
Offer
0.85
Volume
108,022
0.82 Day's Range 0.88
0.38 52 Week Range 0.90
Market Cap
Previous Close
0.85
Open
0.85
Last Trade
500
@
0.84
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
112,006
Shares Outstanding
112,792,000
Dividend Yield
-
PE Ratio
-5.96
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-15.89M

About Satellos Bioscience Inc

Sector
Coml Physical, Biologcl Resh
Industry
Pharmaceutical Preparations
Headquarters
Toronto, Ontario, Can
Founded
2007
Satellos Bioscience Inc is listed in the Coml Physical, Biologcl Resh sector of the Toronto Stock Exchange with ticker MSCL. The last closing price for Satellos Bioscience was $0.85. Over the last year, Satellos Bioscience shares have traded in a share price range of $ 0.38 to $ 0.90.

Satellos Bioscience currently has 112,792,000 shares in issue. The market capitalisation of Satellos Bioscience is $95.87 million. Satellos Bioscience has a price to earnings ratio (PE ratio) of -5.96.

MSCL Latest News

Satellos to Participate in November 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...

Satellos Announces Participation in September 2024 Investor Conferences

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience...

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to...

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-1.176470588240.850.890.811085800.84763591CS
40.1929.23076923080.650.90.61831900.76874258CS
120.36576.84210526320.4750.90.451120060.66690655CS
260.36750.480.90.45781180.61314527CS
520.2235.48387096770.620.90.38756690.59628454CS
1560.2235.48387096770.620.90.38756690.59628454CS
2600.2235.48387096770.620.90.38756690.59628454CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRNGreenlane Renewables Inc
$ 0.12
(41.18%)
2.29M
NUMINuminus Wellness Inc
$ 0.09
(28.57%)
3.28M
FFH.UFairfax Financial Holdings Limited
US$ 1,350.28
(25.00%)
100
CURACuraleaf Holdings Inc
$ 2.84
(21.89%)
1.24M
SHOPShopify Inc
$ 151.35
(20.72%)
6.32M
FCUFission Uranium Corp
$ 0.72
(-21.74%)
12.55M
COPRCoppernico Metals Inc
$ 0.30
(-18.92%)
1.12M
CSCICOSCIENS Biopharma Inc
$ 3.94
(-17.05%)
5.66k
GMTNGold Mountain Mining Corp
$ 0.05
(-16.67%)
163.8k
MDNAMedicenna Therapeutics Corp
$ 1.78
(-14.01%)
433.56k
ENBEnbridge Inc
$ 58.82
(-1.21%)
16.33M
FCUFission Uranium Corp
$ 0.72
(-21.74%)
12.55M
MFCManulife Financial Corporation
$ 45.39
(0.62%)
8.13M
SUSuncor Energy Inc
$ 53.13
(-1.74%)
7.09M
BITFBitfarms Ltd
$ 3.77
(2.72%)
6.85M

Discussion

View Full Feed
No Posts Found

Your Recent History

Delayed Upgrade Clock